1. Prevalence in the population and relationship between symptoms and x-ray changes;S, Lawrence J.; M, Bremner J.; Osteoarthrosis, Bier F.;Ann Rheum Dis,1966
2. Clinical trials in the rheumatic diseases: a selected clinical review;Rosenbloom, D.; Brooks, P.M.; Bellamy, N.; Buchanan, W.W.,1985
3. Minutes ofthe 19th meeting ofthe FDA Arthritis Advisory Committee, Food and Drug Administration;F, Hershey D.; H, Weisman H.;Washington DC: Food and Drug Administration
4. Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam;P, Pruss T.; H, Stroissnig; S, Radhofer-Welte;Postgrad Med,1990
5. Ankier S I, Brimelow A E, Crome P, et al. Chlortenoxicam pharmacokinetics in young and elderly volunteers. I'ostgrad Med J 1988; 64: 752-4.